CompanyGraph
What stands out
- Valued far above the size of its business
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $195.68M, lower than 95% of all stocks globally
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
6.31BTWD195.68M · vs all stocks (USD)
Trailing P/E
148.83xvs Biotechnology peers
Revenue (TTM)
258.93MTWD8.02M · vs all stocks (USD)
Profit Margin
20.66%vs Biotechnology peers
Beta
0.1880xvs all stocks
52-Week Change
7.00%vs all stocks
Market Capitalization
6.31BTWD195.68M · vs all stocks (USD)
Enterprise Value
5.41BTWD167.62M · vs all stocks (USD)
Trailing P/E
148.83xvs Biotechnology peers
Price to Sales (TTM)
24.55xvs Biotechnology peers
Price to Book (MRQ)
6.07xvs Biotechnology peers
Enterprise to Revenue
20.89xvs Biotechnology peers
Enterprise to EBITDA
68.90xvs Biotechnology peers
Gross Margin
98.33%vs Biotechnology peers
Profit Margin
20.66%vs Biotechnology peers
Operating Margin
-340.76%vs Biotechnology peers
Return on Assets (TTM)
4.13%vs Biotechnology peers
Return on Equity (TTM)
5.11%vs Biotechnology peers
Revenue (TTM)
258.93MTWD8.02M · vs all stocks (USD)
Revenue per Share (TTM)
0.3620TWDUpdated Jul 15, 2026Quarterly Revenue Growth
-5.00%vs Biotechnology peers
Gross Profit (TTM)
241.77MTWD7.49M · vs all stocks (USD)
EBITDA (TTM)
73.39MTWD2.27M · vs all stocks (USD)
Net Income (TTM)
53.51MTWD1.66M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
2104.37%vs Biotechnology peers
Operating Cash Flow (TTM)
64.82MTWD2.01M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
36.39MTWD1.13M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00TWDUpdated Jul 15, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
259.47MTWDFY2025 · Dec 31, 2025Cost of Goods Sold
18.17MTWDFY2025 · Dec 31, 2025Gross Profit
241.30MTWDFY2025 · Dec 31, 2025Operating Income
69.39MTWD2.15M · vs all stocks (USD)
Pre-tax Income
57.44MTWDFY2025 · Dec 31, 2025Income Tax Expense
12.26MTWDFY2025 · Dec 31, 2025Net Income
45.18MTWDFY2025 · Dec 31, 2025EBIT
59.11MTWDFY2025 · Dec 31, 2025EBITDA (Income Statement)
73.39MTWDFY2025 · Dec 31, 2025Research & Development
96.88MTWDFY2025 · Dec 31, 2025Selling, General & Administrative
75.02MTWDFY2025 · Dec 31, 2025Non-operating Interest Income
18.47MTWDFY2025 · Dec 31, 2025Non-operating Interest Expense
1.67MTWDFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00TWDFY2025 · Dec 31, 2025Operating Cash Flow
-4.67MTWDFY2025 · Dec 31, 2025Free Cash Flow
-9.87MTWDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
145.09MTWDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
57.44MTWDFY2025 · Dec 31, 2025Stock-based Compensation
-11.63MTWDFY2025 · Dec 31, 2025Other Non-cash Items
-16.80MTWDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
2.54MTWDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-36.22MTWDFY2025 · Dec 31, 2025Capital Expenditures
5.20MTWDFY2025 · Dec 31, 2025Net Intangibles (CF)
-3.06MTWDFY2025 · Dec 31, 2025Purchase of Investments
-643.66MTWDFY2025 · Dec 31, 2025Sale of Investments
701.80MTWDFY2025 · Dec 31, 2025Other Investing Activity
2.03MTWDFY2025 · Dec 31, 2025Net Investing Cash Flow
65.36MTWDFY2025 · Dec 31, 2025Net Short-term Debt Issuance
35.00MTWDFY2025 · Dec 31, 2025Common Stock Repurchase
-57.27MTWDFY2025 · Dec 31, 2025Net Financing Cash Flow
-22.27MTWDFY2025 · Dec 31, 2025Shares Outstanding
711.83MSharesUpdated Jul 15, 2026Float Shares
435.48MSharesUpdated Jul 15, 2026% Held by Insiders
32.69%vs all stocks
% Held by Institutions
14.47%vs all stocks
Total Cash (MRQ)
960.94MTWD29.78M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.35TWDUpdated Jul 15, 2026Total Debt (MRQ)
12.83MTWD397.58K · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0122xvs Biotechnology peers
Current Ratio (MRQ)
19.34xvs Biotechnology peers
Book Value per Share (MRQ)
1.47TWDUpdated Jul 15, 2026Total Assets
1.17BTWD36.17M · vs all stocks (USD)
Total Current Assets
1.12BTWDFY2025 · Dec 31, 2025Total Liabilities
92.38MTWDFY2025 · Dec 31, 2025Total Non-current Assets
47.31MTWDFY2025 · Dec 31, 2025Total Non-current Liabilities
9.27MTWDFY2025 · Dec 31, 2025Total Current Liabilities
83.11MTWDFY2025 · Dec 31, 2025Cash & Cash Equivalents
145.09MTWDFY2025 · Dec 31, 2025Other Short-term Investments
881.66MTWDFY2025 · Dec 31, 2025Accounts Receivable
5.01MTWDFY2025 · Dec 31, 2025Inventory
76.10MTWDFY2025 · Dec 31, 2025Short-term Debt
40.59MTWDFY2025 · Dec 31, 2025Other Current Liabilities
5.47MTWDFY2025 · Dec 31, 2025Long-term Debt
8.62MTWDFY2025 · Dec 31, 2025Common Stock (Book)
20.77MTWDFY2025 · Dec 31, 2025Retained Earnings
589.18MTWDFY2025 · Dec 31, 2025Total Shareholders' Equity
1.07BTWD33.31M · vs all stocks (USD)
Treasury Stock
0.00TWDFY2025 · Dec 31, 202552-Week Low
7.44TWDUpdated Jul 15, 202652-Week High
16.40TWDUpdated Jul 15, 202652-Week Change
7.00%vs all stocks
Beta
0.1880xvs all stocks
50-Day MA
9.04TWDUpdated Jul 15, 2026200-Day MA
10.67TWDUpdated Jul 15, 2026Avg 10-Day Volume
1.11MSharesUpdated Jul 15, 2026Avg 30-Day Volume
1.34MSharesUpdated Jul 15, 2026Diluted EPS (TTM)
0.0600TWDUpdated Jul 15, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 24.55Revenue Growth YoY: -0.05
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $195.68M, lower than 95% of all stocks globallySignificant
Market cap (USD): 195,676,169.241Global P5: 269,387,740.27
Revenue is $8.02M, lower than 95% of all stocks globallySignificant
Revenue (USD): 8,024,623.594Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
RxSight Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sillajen Inc.
Tier 1ProductionApproval-Gated PipelineRule
LENZ Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
ImmuneOncia Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Camp4 Therapeutics Corp.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Onward Medical
Tier 1ProductionApproval-Gated PipelineRule
Minerva Neurosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Voyager Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Humedix Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tonix Pharmaceuticals Holding Corp.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Classys Inc.
2 interpretationsOperating Income Growing With Multi-Year Revenue GrowthIndustry-Benchmarked ROA and Margin Elevated
Pharma Research Products Co., Ltd
2 interpretationsOperating Income Growing With Multi-Year Revenue GrowthIndustry-Benchmarked ROA and Margin Elevated
Shenyang Xingqi Pharmaceutical Co., Ltd.
2 interpretationsOperating Income Growing With Multi-Year Revenue GrowthIndustry-Benchmarked ROA and Margin Elevated